New combo pill shows promise for HIV patients fighting TB
NCT ID NCT04734652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new HIV medication (Biktarvy) taken twice daily in 122 adults who also have drug-sensitive tuberculosis (TB) and are on standard TB treatment. The goal was to see if the new pill can control HIV just as well as the current standard treatment. The study measured how many people had undetectable HIV levels after 24 and 48 weeks, while also monitoring safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CAPRISA Springfield Clinical Research Site
Durban, KwaZulu-Natal, 4001, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a robot help stroke survivors with HIV walk again?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- Can a Father-Focused program curb HIV, substance abuse, and violence?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test